Please login to the form below

BeiGene

This page shows the latest BeiGene news and features for those working in and with pharma, biotech and healthcare.

BeiGene bags FDA approval for first product Brukinsa in lymphoma

stage. It’s just the first of several cancer drugs BeiGene is hoping to bring to the US market. ... BeiGene said it will launch Brukinsa in the coming weeks, but hasn’t yet revealed its pricing plans.

Latest news

Amgen buys BeiGene stake for $2.7bn to aid push into China

Amgen has agreed to buy a 20.5% stake in Chinese drugmaker BeiGene in a $2.7bn deal that will expand its presence in the Chinese cancer market. ... Meanwhile, Amgen says it will also pay royalties to BeiGene on the sales of these products outside of China
BeiGene gets speedy US review for lymphoma drug zanubrutinib

First US filing is major milestone for Chinese firm. Chinese biopharma company BeiGene has claimed priority review status for its BTK inhibitor zanubrutinib from the FDA, setting up a possible approval ... It’s a major milestone for BeiGene,
Hansoh Pharma shares head skyward after HKEX debut

including BeiGene and WuXi AppTec, after changing regulations to allow companies without revenues or profits to list on the HKEX.
Chi-Med goes for third IPO in Hong Kong

Last August, BeiGene raised a whopping $903m in its HKEX debut, near the top of its target range, to help it fund its own portfolio of cancer drugs headed by
China’s BeiGene raises $903m from Hong Kong IPO

BeiGene recently said it had completed enrolment in a phase III trial of zanubrutinib in Waldenström macroglobulinemia and could file for approval in the US in mid-2019. ... BeiGene’s shares are expected to begin trading on the HKEX on 8 August under

More from news
Approximately 8 fully matching, plus 3 partially matching documents found.

Latest Intelligence

Chinese biotech’s global ambitions

BeiGene says it as headed off any such concens by working with well-established pharma company and contract manufacturer Boehringer Ingelheim to manufacture its drug. ... Meanwhile, BeiGene is also looking to break into the still all-important US market.
Biopharma's Future: Made in China

The rise of Chinese biopharma. One home-grown pharma company which could replicate this accomplishment is Beijing-headquartered BeiGene. ... BeiGene’s CEO John Oyler told a Goldman Sachs recent conference that a Chinese biopharma sector was ready to
Deal Watch March 2017

In particular, the third largest deal of the month is a joint venture between the research-based biotechnology company, BeiGene, which focuses on immuno-oncology, and the Guangzhou Development District. ... The agreement, worth $330m, will build BeiGene
Deal Watch table for November 2013

BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.

More from intelligence
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Senior Editor - Medical Communications - South East - Buckingham...: Highly competitive salary &package

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Executive: Salary TBC

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Account Supervisor: Salary TBC

Entry Level Editorial Assistant – Medical Education –Buckinghams...: Highly Competitive

Graduate Scientific Editor: DOE

Account Director, Medical Education: Salary TBC

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Editorial Team Leader – Medical Communications – Buckinghamshire...: Salary TBC

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Account Director: Salary TBC

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Scientific Director - Medical Communications - Berkshire: Excellent package on offer

Senior Medical Writer: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment: Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game: Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....
Early diagnosis underpins NHS cancer strategy: Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan...